248 related articles for article (PubMed ID: 25474006)
1. Clinical management and burden of prostate cancer: a Markov Monte Carlo model.
Sanyal C; Aprikian A; Cury F; Chevalier S; Dragomir A
PLoS One; 2014; 9(12):e113432. PubMed ID: 25474006
[TBL] [Abstract][Full Text] [Related]
2. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
Sanyal C; Aprikian AG; Cury FL; Chevalier S; Dragomir A
Cancer; 2016 Apr; 122(7):1085-96. PubMed ID: 26828716
[TBL] [Abstract][Full Text] [Related]
3. Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
Hoffman RM; Koyama T; Albertsen PC; Barry MJ; Daskivich TJ; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Potosky AL; Penson DF
J Gen Intern Med; 2015 Jul; 30(7):924-34. PubMed ID: 25678374
[TBL] [Abstract][Full Text] [Related]
4. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
6. Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.
Mühlberger N; Boskovic K; Krahn MD; Bremner KE; Oberaigner W; Klocker H; Horninger W; Sroczynski G; Siebert U
BMC Public Health; 2017 Jun; 17(1):596. PubMed ID: 28651567
[TBL] [Abstract][Full Text] [Related]
7. A decision analysis for treatment of clinically localized prostate cancer.
Kattan MW; Cowen ME; Miles BJ
J Gen Intern Med; 1997 May; 12(5):299-305. PubMed ID: 9159699
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis.
Liu D; Lehmann HP; Frick KD; Carter HB
J Urol; 2012 Apr; 187(4):1241-6. PubMed ID: 22335873
[TBL] [Abstract][Full Text] [Related]
9. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer.
Cerantola Y; Dragomir A; Tanguay S; Bladou F; Aprikian A; Kassouf W
Urol Oncol; 2016 Mar; 34(3):119.e1-9. PubMed ID: 26602178
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database.
Preisser F; Bandini M; Mazzone E; Nazzani S; Marchioni M; Tian Z; Saad F; Pompe RS; Shariat SF; Heinzer H; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Focus; 2019 Sep; 5(5):807-814. PubMed ID: 29802052
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration.
Shao Q; Ouyang J; Fan Y; Xie J; Zhou J; Wu J; Karim Kader A; Xu J; Liu G; Shan Y; Wen D; Zhang Y
Cancer Lett; 2012 Feb; 315(2):170-7. PubMed ID: 22099876
[TBL] [Abstract][Full Text] [Related]
13. Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis.
Parikh R; Sher DJ
Cancer; 2012 Jan; 118(1):258-67. PubMed ID: 21720990
[TBL] [Abstract][Full Text] [Related]
14. Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis.
Lester-Coll NH; Goldhaber SZ; Sher DJ; D'Amico AV
Cancer; 2013 May; 119(10):1808-15. PubMed ID: 23400678
[TBL] [Abstract][Full Text] [Related]
15. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.
Mold JW; Holtgrave DR; Bisonni RS; Marley DS; Wright RA; Spann SJ
J Fam Pract; 1992 May; 34(5):561-8. PubMed ID: 1578205
[TBL] [Abstract][Full Text] [Related]
16. Optimal management of high-risk T1G3 bladder cancer: a decision analysis.
Kulkarni GS; Finelli A; Fleshner NE; Jewett MA; Lopushinsky SR; Alibhai SM
PLoS Med; 2007 Sep; 4(9):e284. PubMed ID: 17896857
[TBL] [Abstract][Full Text] [Related]
17. Long-term medical costs and life expectancy of acute myeloid leukemia: a probabilistic decision model.
Wang HI; Aas E; Howell D; Roman E; Patmore R; Jack A; Smith A
Value Health; 2014 Mar; 17(2):205-14. PubMed ID: 24636378
[TBL] [Abstract][Full Text] [Related]
18. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
[TBL] [Abstract][Full Text] [Related]
19. Treatment for patients with rectal cancer and a clinical complete response to neoadjuvant therapy: a decision analysis.
Neuman HB; Elkin EB; Guillem JG; Paty PB; Weiser MR; Wong WD; Temple LK
Dis Colon Rectum; 2009 May; 52(5):863-71. PubMed ID: 19502849
[TBL] [Abstract][Full Text] [Related]
20. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.
Sammon JD; Abdollah F; D'Amico A; Gettman M; Haese A; Suardi N; Vickers A; Trinh QD
Eur Urol; 2015 Nov; 68(5):756-65. PubMed ID: 25819724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
